-
Meet Sri: Nicoya’s SVP of Marketing and Product
With Sri’s energy, vision, and strategic direction, we’re ready to leap into the next chapter of our growth. One of the most exciting developments in our year so far has been the addition of Dr. S...
-
Shaping the future of therapeutic antibodies with Digital SPR
We spent a week with innovators of antibody therapeutics to learn how we can enhance development from bench to bedside By Mike Piazza, Associate Director of Applications Development We recently had th...
-
The future of biosimilars: How emerging technologies are paving the way
Next-generation methods that streamline biosimilar expression and characterization are imperative to lowering the cost of development and maximizing market growth. Biosimilars have delivered on their ...
-
Keeping up with viral evolution: How SPR streamlines prevention and treatment of influenza
Our next generation SPR platforms provide high-quality data and streamline research workflows to give you an edge in the fight against influenza. Influenza viruses cause respiratory infections in huma...
-
SPR vs ELISA: Comparing techniques for biomolecular detection
Binding analysis with surface plasmon resonance (SPR) provides both affinity and kinetics data, giving you the bigger picture. As one of the most standardized and well-characterized immunoassays perfo...
-
2022 wrapped: Celebrating 10 years at Nicoya
We took a moment to look back on the key events that shaped this milestone year. By Ryan Denomme, Co-Founder and CEO Quick links A year of milestones What’s new for our users? Learnings from the fie...
-
SPR vs BLI: Comparing label-free tools for Fc receptor characterization
Alto™ streamlines the characterization of Fc gamma receptors in our latest app note comparing analysis with Digital SPR and BLI. Fc receptors (FcR), named for their binding specificity to the fragme...
-
New Nature study reveals insights into de novo autoreactivity in severe COVID-19 using Alto™ Digital SPR
Kinetic analysis of de novo autoreactivity in severe COVID-19 reveals important implications for early intervention and treatment in patients with post-COVID sequelae. The SARS-CoV-2 outbreak was firs...
-
Targeting interleukins: How digital SPR accelerates monoclonal antibodies for immune-related diseases
Alto’s unmatched ability to seamlessly characterize mAbs make it the optimal fit for biologics developers. Read our latest application note on digital SPR analysis of the interleukin-6 receptor (IL-...
-
Cancer detection using SPR: Announcing our partnership with INOVIQ
The SubB2M™-based SPR test will detect for pan-cancer biomarker Neu5Gc in blood samples on Alto™, and will initially be used as a cancer risk assessment test. We’re excited to announce our partn...
